RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new analyses from studies of sotatercept, Merck’s novel investigational activin ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

Merck is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world. The drugmaker will cut administrative, ...

Merck's biggest cash cow could soon face competition from two drugs in development. However, the company is working on ways to get around this potential headwind. These are all good things, none of ...

No matter how well the stock market is performing, investors can always find some companies that aren't keeping pace with broader equities. This year, pharmaceutical giant Merck (NYSE: MRK) is it: The ...

While increasing collaboration between payers and providers was a major theme at HIMSS in Orlando last week, one other major stakeholder has been quite a bit harder to find in conversations about big ...

In the latest trading session, Merck (MRK) closed at $111.11, marking a +1.52% move from the previous day. The stock ...

Merck's Keytruda should continue growing its sales until it faces a patent cliff in 2028. The company is developing other medicines to deal with mounting competition. Merck is also a solid choice for ...

Michael Rosenblatt, dean of Tufts University School of Medicine (TUSM), yesterday morning announced his decision to step down effective Dec. 20. He will take up the newly created position of chief ...